Tevapharm

What to Know About Schizophrenia

Schizophrenia is a chronic, progressive and severely debilitating mental disorder that affects how one thinks, feels and acts. Patients experience many symptoms, including delusions, hallucinations, disorganized speech or behavior and impaired cognitive ability. 01

~24
million worldwide		 3.5
million in the U.S.
 

Approximately 24 million people worldwide and 3.5 million people in the U.S. are currently diagnosed with schizophrenia. 02

Early 20s
for men		 Late 20s
for women
 

Although schizophrenia can occur at any age, the average age of onset tends to be in the late teens to early 20s for men, and late 20s to early 30s for women. 03

 
In epidemiological surveys, approximately 40% of the respondents with schizophrenia report that they have not received
any mental health treatments in the preceding 6–12 months. 04		 40percent-piechart.jpg
 
Relapse continues to be an ongoing and complex challenge faced by many schizophrenia patients, with rates estimated to be between 50-92% globally. 05 50to92percent-piechart.jpg

Each relapse carries a biological risk, including:

Changes in brain morphology

Loss of day-to-day function

Treatment resistance

Download as PDF
 

Find out more

References

  1. Back to contents.

    Substance Abuse and Mental Health Services Administration. Schizophrenia. https://www.samhsa.gov/mental-health/schizophrenia. Accessed November 2023. Velligan DI, Rao S. The epidemiology and global burden of schizophrenia. J Clin Psychiatry. 2023;84(1):MS21078COM5. https://doi.org/10.4088/JCP.MS21078COM5. Wander C. (2020). Schizophrenia: opportunities to improve outcomes and reduce economic burden through managed care. The American journal of man aged care, 26(3 Suppl), S62–S68. https://doi.org/10.37765/ajmc.2020.43013

  2. Back to contents.

    Velligan DI, Rao S. The epidemiology and global burden of schizophrenia. J Clin Psychiatry. 2023;84(1):MS21078COM5.
    https://doi.org/10.4088/JCP.MS21078COM5. Wander C. (2020). Schizophrenia: opportunities to improve outcomes and reduce economic burden through managed care. The Ameri can journal of managed care, 26(3 Suppl), S62–S68. https://doi.org/10.37765/ajmc.2020.43013 World Health Organization. (n.d.). Schizophrenia. World Health Organization. https://www.who.int/newsroom/fact-sheets/detail/schizophrenia

  3. Back to contents.

    Substance Abuse and Mental Health Services Administration. Schizophrenia. https://www.samhsa.gov/mental-health/schizophrenia. Accessed November
    2023.

  4. Back to contents.

    Mojtabai R, Fochtmann L, Chang SW, Kotov R, Craig TJ, Bromet E. Unmet need for mental health care in schizophrenia: an overview of literature and new data from a first -admission study. Schizophr Bull. 2009 Jul;35(4):679-95. doi: 10.1093/schbul/sbp045. Epub 2009 Jun 8. PMID: 19505994; PMCID: PMC2696378.

  5. Back to contents.

    Emsley, R., & Kilian, S. (2018). Efficacy and safety profile of paliperidone palmitate injections in the management of patients with schizophrenia: an evidence-based review. Neuropsychiatric disease and treatment, 14, 205–223. Emsley, R., Chiliza, B., Asmal, L. et al. (2013) The nature of relapse in schizophrenia. BMC Psychiatry 13, 50. Andreasen, N. C., et al. (2013). Relapse duration, treatment intensity, and brain tissue loss in schizophrenia: a prospective longitudinal MRI study. The American journal of psychiatry, 170(6), 609–615.

©2024 Teva Neuroscience, Inc. PSYCH-40618 May 2024